Study # ACE-Breast-03

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd

Study Status:

Enrolling

Treatment Agent:

ARX788

Description

Short Title: ACE-Breast-03

Phase 2 study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks via intravenous (IV) infusion.

Resources and Links

National Clinical Trial Identified Number: NCT04829604

Information and next steps

Disease:

  • Breast Cancer, HER2 Positive Metastatic Breast Cancer

Study Phase:

II

Physician Name:

Department:

Ask a Question